Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.
Last trade$0.5119
Day change-$0.0284 (-5.26%)
Day range$0.51 – $0.572
Volume2,909,147
Market cap$150M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$150.01M
Price / earnings
—
Price / book
8.3×
Price / sales
62.61×
EV / sales
63.43×
EV / EBITDA
-1.44×
Profitability
Earnings per share
-$0.34
Return on assets
-75.47%
Return on equity
-524.6%
Dividend yield
0%
Liquidity and leverage
Debt / equity
3.68×
Current ratio
3.34×
Quick ratio
3.11×
Cash ratio
2.61×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$88.58M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for HUMA, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$1.03M
$406K
$495K
$467K
$753K
$301K
$517K
$0
Cost of revenue
$1.43M
$1.23M
$2.04M
$9.08M
$260K
$213K
$147K
$0
Gross profit
-$401K
-$825K
-$1.54M
-$8.62M
$493K
$88K
$370K
$0
Selling, general and administrative
$9.01M
$8.03M
$7.93M
$7.62M
$7.61M
$7.81M
$8.14M
$7.43M
Research and development
$14.1M
$18.14M
$19.46M
$14.61M
$17.27M
$22.01M
$15.42M
$20.66M
Total operating expenses
$19.73M
$28.89M
$27.39M
$22.22M
$19.99M
$35.29M
$23.55M
$28.09M
Operating income
-$20.13M
-$29.71M
-$28.94M
-$30.84M
-$19.5M
-$35.2M
-$23.18M
-$28.09M
Interest expense
-$2.37M
-$2.32M
-$2.27M
-$3.09M
-$2.61M
-$2.55M
-$3M
-$2.51M
Income before taxes
-$15.54M
-$36.8M
-$17.62M
-$24.8M
-$17.51M
-$37.66M
$39.14M
-$20.94M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$15.54M
-$36.8M
-$17.62M
-$24.8M
-$17.51M
-$37.66M
$39.14M
-$20.94M
Net income attributable to common shareholders
-$15.54M
-$36.8M
-$17.62M
-$24.8M
-$17.51M
-$37.66M
$39.14M
-$20.94M
EBITDA
-$18.86M
-$28.38M
-$27.59M
-$31.07M
-$18.16M
-$33.86M
-$21.88M
-$28.37M
Basic earnings per share
-$0.06
-$0.16
-$0.09
-$0.13
-$0.11
-$0.24
$0.28
-$0.16
Diluted earnings per share
-$0.06
-$0.16
-$0.09
-$0.13
-$0.11
-$0.24
$0.28
-$0.16
Recent news
Company coverage with links to the original publishers.
Humacyte, Inc. (HUMA) reported a quarterly loss of $0.07 per share, beating consensus estimates of $0.09 loss, with a 22.22% earnings surprise. Revenue reached $1.03 million, surpassing estimates by 19.54%. However, the stock has declined 52.6% year-to-date versus the S&P 500's 10.3% gain. The company holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market.
RenovoRx (RNXT) reported a quarterly loss of $0.07 per share, missing the consensus estimate of $0.05 loss by 40%, though revenues of $1.07 million exceeded expectations by 1.52%. The stock has gained 55.9% year-to-date, outperforming the S&P 500's 12.3% gain. The company holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market.
Humacyte, Inc. (HUMA) stock fell 12.11% on November 5, 2026, significantly outpacing the broader market decline of 4.36%. The company is scheduled to report earnings on November 10, 2026, with projected EPS of -$0.09 and revenue of $0.86 million. For the full year, Zacks projects earnings of -$0.4 per share and revenue of $4.05 million. The stock currently holds a Zacks Rank of #3 (Hold).
Humacyte, Inc. (HUMA) closed at $0.41, down 13.01% in the latest trading session, significantly underperforming the S&P 500's 1.82% decline. The stock has fallen 6.58% over the past month while the Medical sector gained 5.28%. Upcoming earnings are expected to show an EPS of -$0.09 with revenue of $0.86 million, though full-year projections show mixed results. The company holds a Zacks Rank #3 (Hold) rating.
Humacyte, Inc. (HUMA) rose 1.28% to $0.41 in the latest session, outperforming the S&P 500's 0.58% gain. However, the stock has declined 30.34% over the past month, significantly underperforming the Medical sector's 3.5% gain. The company holds a Zacks Rank #3 (Hold) with projected quarterly EPS of -$0.09 and revenue of $0.86 million, though annual estimates show mixed signals with declining earnings but nearly doubled revenue.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.